Peng L, He J, Zheng Y, Zeng Q. Effects of monoclonal antibody daratumumab combined with ixazomib-based treatment regimen on survival of patients with relapsed/refractory multiple myeloma. Vojnosanit Pregl [Internet]. 2025 Apr. 29 [cited 2026 Jul. 12];82(04). Available from: https://asistent.ceon.rs/index.php/vsp/article/view/48120